Liminatus Pharma, Inc. Class A Common Stock
The research page contains a warning that has not been mapped to a supported model interpretation. The company research remains available, but the complete score is withheld until the warning is reviewed.
LIMN · Price history
Price at last available close
$2.90
−$0.83 (-22.25%) 1M
2026-10-29
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Liminatus Pharma, Inc. Class A Common Stock
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
How they make money
Liminatus Pharma, Inc. is a pre-clinical stage biopharmaceutical company that does not currently generate revenue from product sales. The company focuses on developing novel cancer therapies, specifically monoclonal antibodies, and relies on external financing to fund its research, development, and operational activities.
Products & services
The company's lead clinical candidate is IBA101, a humanized anti-CD47 monoclonal antibody designed to block the CD47 'do not eat me' signal on cancer cells to restore immune-cell phagocytosis.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer categories were not separately identified in the reviewed source set.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for drug substance and finished product; specific supplier names are unnamed.Source
Business relationships & partnerships
- InnoBation Bio Co. Ltd. — The company licenses its CD47 asset from InnoBation Bio Co. Ltd.Source
Strengths
- Development of novel cancer therapies targeting the CD47 immune checkpointSource
Sources
Company-specific research
Questions worth answering for LIMN
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can LIMN fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is LIMN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for LIMN to reach sustainable profitability?
- •What future growth or profitability would be needed to justify LIMN's current valuation?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of LIMN's score?
Essential Investment Snapshot
Market Cap
$3.9M
P/E Ratio
-0.2
EPS
$-23.70
52-Week High
$141.50
52-Week Low
$3.29
Beta
0.71
Shares Outstanding
1.3M
Total Debt
$1.4M
Dividend
No current dividend
Liquidation Value / Share
$0.22
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Elevated movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for LIMN
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-13.7x). Earnings may be strained to cover interest expense.
Reverse-split headline · Aug 18, 2026
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
GlobeNewsWireCommunity Sentiment
0 active · 0 total callsNo personal call yet on LIMN.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Development of novel cancer therapies targeting the CD47 immune checkpoint.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Pre-clinical stage status with no history of revenue and significant accumulated deficits.
- −Dependence on third-party contract manufacturers for production.
- −Nasdaq listing deficiency risks related to market value and minimum bid price.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$2.90
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· |
| Cost of Revenue | $986.00 | $0.00 | $0.00 | $0.00 | ···· | ···· |
| Gross Profit | -$986.00 | $0.00 | $0.00 | $0.00 | ···· | ···· |
| Research & Development | $1.0M | $0.00 | $2.7M | $3.8M | ···· | ···· |
| SG&A Expenses | $3.1M | $3.0M | $645K | $1.1M | ···· | ···· |
| Operating Expenses | $4.1M | $3.0M | $2.9M | $2.6M | ···· | ···· |
| EBITDA | -$12.4M | -$10.0M | -$2.7M | -$1.1M | ···· | ···· |
| Operating Income | -$4.1M | -$3.0M | -$2.9M | -$2.6M | ···· | ···· |
| Interest Expense | $76K | $216K | $138K | $175K | ···· | ···· |
| Income Before Tax | -$12.5M | -$10.2M | -$2.9M | -$1.2M | ···· | ···· |
| Income Tax Expense | $0.00 | $0.00 | $19K | $34K | ···· | ···· |
| Net Income | -$12.5M | -$10.2M | -$2.9M | -$1.2M | ···· | ···· |
| Basic EPS | $-23.70 | $-21.50 | $-20.00 | $-7.50 | ···· | ···· |
| Basic Shares | 475K | 475K | 144K | 160K | ···· | ···· |
| Diluted Shares | 475K | 475K | 144K | 160K | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$2.96
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
No material change
Cash Change
+125.5%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Cash position grew
Potential Score Impact
Positive indicators included cash levels. Pressure indicators included EPS growth, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS declined 1308.2%. Cash increased 125.5%. Total debt was essentially unchanged.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
3 historical recordsHistorical Score Chart
3 of 3 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
Rumor Mill · LIMN
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial